Early serum miR-1297 is an indicator of poor neurological outcome in patients with aSAH

Abstract

Objective: MiRNAs are important regulators of translation and have been described as biomarkers of a number of cardiovascular diseases, including stroke. The purpose of the study was to determine expression levels of serum miR-1297 in patients with aneurysmal subarachnoid hemorrhage (aSAH), and to assess whether miR-1297 was the prognostic indicator of aSAH. Methods: We treated 128 aSAH patients with endovascular coiling. The World Federation of Neurological Surgeons (WFNS) grades, Hunt–Hess grades, and modified Fisher scores were used to assess aSAH severity. Neurologic outcome was assessed using the Modified Rankin Scale (mRS) at 1-year post-aSAH. Serum was taken at various time points (24, 72, and 168 h, and 14 days). Serum samples from aSAH patients and healthy controls were subjected to reverse transcription (RT) quantitative real-time PCR (RT-qPCR). Results: A poor outcome at 1 year was associated with significantly higher levels of miR-1297 value at the four time points, higher WFNS grade, higher Hunt–Hess grade, and higher Fisher score. Serum miR-1297 levels were significantly higher in patients, compared with healthy controls. There were significant correlations of miR-1297 concentrations in serum with severity in aSAH. The AUCs of miR-1297 at the four time points for distinguishing the aSAH patients from healthy controls were 0.80, 0.94, 0.77, and 0.59, respectively. After multivariate logistic regression analysis, only miR-1297 at 24 and 72 h enabled prediction of neurological outcome at 1 year. Conclusion: Serum was an independent predictive factor of poor outcome at 1 year following aSAH. This result supports the use of miR-1297 in aSAH to aid determination of prognosis.

Systemic exosomal miR-193b-3p delivery attenuates neuroinflammation in early brain injury after subarachnoid hemorrhage in mice

“…Previous studies demonstrated that miRNAs were involved in numerous physiological/pathological processes and were particularly appealing diagnostic and therapeutic tools for various diseases, including stroke, Parkinson's disease, traumatic brain injury (TBI), and Alzheimer's disease. Despite the fact that expression levels of miRNAs have measured in cerebrospinal fluid and in circulation, there are few studies investigating changes of miRNAs after SAH [12][13][14]. The blood-brain barrier (BBB) has been proven to be a major obstacle for delivery of drugs to the brain.…”

MicroRNAs as Biomarkers for Predicting Complications following Aneurysmal Subarachnoid Hemorrhage

“…The use of biofluid miRNA biomarkers in aSAH has been explored in a number of recent studies (Table 2). Encouraging data confirm that dysregulated miRNA expression is associated with aSAH, DCV, and DCI, and that changes can be observed in biofluids and circulating blood cells [62,63,[68][69][70][71][72][73][74][75][76][77][78][79][80][81]. Importantly, altered miRNA expression levels in biofluids following aSAH are temporally dynamic and are most noticeable within the first 3 days post-ictus [62,69,71,75,77,81].…”

“…Changes in miRNAs following aSAH have been implicated in prognosis in several studies. Elevated CSF miR-9-3p and miR-9-5p are associated with poor functional outcome [69], and serum miR-502-5p and miR-1297 may help predict neurological outcome [72,77,78]. Unfortunately, to date no miRNA has been identified that significantly associates with DCI [68,69].…”

miRNA Profiling of Circulating Small Extracellular Vesicles From Subarachnoid Hemorrhage Rats Using Next-Generation Sequencing

“…Many studies have shown that there is a close relationship between SAH and miRNA in a variety of physiological and pathological aspects, such as signal pathway level, cellular level, and so on, and predict that miRNA will become one of the effective methods for the treatment of SAH in the future ( Su et al, 2015 ; Chen et al, 2017 ). It not only participates in inflammation, neuronal apoptosis, synaptic remodeling, and many other cellular functions but also detects the differential expression of miRNA in blood, cerebrospinal fluid (CSF) of SAH patients, and MCA of SAH model in rats ( Kikkawa et al, 2017 ; Sheng et al, 2018a , b ). Many disorders of miRNA expression are involved in the occurrence and development of CVS, and the detection of miRNA in EVs can be used as a new standard to prevent, diagnose, and judge the prognosis of CVS after SAH.…”